Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: GENETIC: fluorescence in situ hybridization|OTHER: immunohistochemistry staining method|OTHER: immunologic technique|OTHER: laboratory biomarker analysis
Sponsor: NSABP Foundation Inc
Collaborators: National Cancer Institute (NCI)